Immuneering to Present Atebimetinib Combination Potential at 2026 Symposium
Immuneering says it will highlight atebimetinib’s potential for combinations in pancreatic and anaplastic thyroid cancers at the 2026 EORTC-NCI-AACR Symposium.
Related stories
TeraWulf Secures Google Backstop for Three Anthropic Data Hall Leases
TeraWulf entered into three credit support agreements with Google to backstop certain Anthropic obligations under leases for data halls CB-1, CB-2 and CB-3 at its Hawesville, Kentu
M impact | EQUITY | Nov 04, 2026, 01:23 PM UTC
Burjeel Holdings Reports Quarterly Profit of 184 Million Dirhams
M impact | EQUITY | Nov 04, 2026, 01:23 PM UTC
Burjeel Holdings Q3’26 Finance Costs Rise 66.5% to AED 62 Million
M impact | EQUITY | Nov 04, 2026, 01:23 PM UTC
Norwegian Air shares rise 5.2%, on track for best day since June
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Shringar House of Mangalsutra Reports Q2 Revenue of INR 8,186.6 Million
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Crédit Mutuel Arkéa Contains Cyberattack; Operations Gradually Resume
The bank said clients’ assets were not affected.
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC